---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-073213"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2026-06-29T21:19:24+00:00"
generated_at: "2026-06-29T21:20:33.364600+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics appoints John P. Sharp interim CFO; board member resigns, classes realigned

## Summary
- John P. Sharp appointed Interim CFO effective June 25, 2026, replacing Quang X. Pham.
- Compensation: $455/hour, up to 24 hours/week via Lohman & Associates Master Services Agreement.
- Steven Zelenkofske resigns from board effective June 30, 2026; no disagreement cited.
- Board realigned: Glynn Wilson moved from Class I to Class III director to balance classes.

## SEC filing metadata
- accession: 0001213900-26-073213
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2026-06-29T21:19:24+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390026073213/0001213900-26-073213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390026073213/ea0296328-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-073213
- JSON: https://secwatch.observer/filing/0001213900-26-073213.json
- Plain text: https://secwatch.observer/filing/0001213900-26-073213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.